CN102488810A - Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases - Google Patents
Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN102488810A CN102488810A CN2011104343492A CN201110434349A CN102488810A CN 102488810 A CN102488810 A CN 102488810A CN 2011104343492 A CN2011104343492 A CN 2011104343492A CN 201110434349 A CN201110434349 A CN 201110434349A CN 102488810 A CN102488810 A CN 102488810A
- Authority
- CN
- China
- Prior art keywords
- huoxiang zhengqi
- soft capsule
- zhengqi ruanjiaonang
- application
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a huoxiangzhengqi soft capsule serving as a medicinal preparation for treating cardiovascular and cerebrovascular diseases, an application of the huoxiangzhengqi soft capsule serving as a medicinal preparation for treating hyperlipemia, an application of the huoxiangzhengqi soft capsule serving as a medicinal preparation for treating hyperglycemia and an application of the huoxiangzhengqi soft capsule serving as a medicinal preparation for treating hypertension. Due to the adoption of the applications, more administration choices can be provided for the clinical treatment of the diseases.
Description
Technical field
The present invention relates to the medical usage of Chinese patent medicine, the application of HUOXIANG ZHENGQI RUANJIAONANG in conduct treatment cardiovascular and cerebrovascular diseases medicament preparation specifically.
Background technology
Ageratum has multiple dosage form; Like HUOXIANG ZHENGQI SHUI; Ageratum drop pill, HUOXIANG ZHENGQI RUANJIAONANG; But its main component all is Herba Pogostemonis, Folium Perillae, Pericarpium Arecae, Poria, the Rhizoma Atractylodis Macrocephalae etc., have induce sweat dampness dissipating, QI regulating with in effect, mainly be used for heatstroke, flu and the gastroenteropathy of treatment due to " heat-damp in summer ".Because mostly the main effective ingredient of ageratum is volatile oil, consider that on effective ingredient reservation and patient's compliance soft capsule is the dosage form that comparatively is fit at present.HUOXIANG ZHENGQI RUANJIAONANG have the dampness dissipating, QI regulating of inducing sweat with in effect, be used for affection of exogenous wind-cold, internal injury humidity hysteresis or the summer Sunstroke flu due to wet, disease sees that headache dusk is heavy, the chest and diaphragm painful abdominal mass is vexed, abdominal distention, vomiting are had loose bowels, and common cold of gastrointestinal type is seen above-mentioned patient.Research worker is carried out extensive studies to the more medical usages of HUOXIANG ZHENGQI RUANJIAONANG at present.
Summary of the invention
The object of the invention just provides a kind of new medical use of HUOXIANG ZHENGQI RUANJIAONANG.
The invention provides the application of HUOXIANG ZHENGQI RUANJIAONANG in conduct treatment cardiovascular and cerebrovascular diseases medicament preparation for this reason.
Cardiovascular and cerebrovascular disease is cardiovascular and cerebrovascular disease general designation.Change along with growth in the living standard and rhythm of life is called as " three-hypers disease " (being hypertension, hyperglycemia and hyperlipidemia) of " affluenza ".Cardiovascular and cerebrovascular disease is that a kind of serious threat is human, the healthy commonly encountered diseases of middle-aged and elderly people more than 50 years old particularly, and every year is died from the number of cardiovascular and cerebrovascular disease up to 1,500 ten thousand people in the whole world, and it is the first to occupy the various causes of the death.At present, China cardiovascular and cerebrovascular disease patient has surpassed 2.7 hundred million people, and China dies from nearly 3,000,000 people of cardiovascular and cerebrovascular disease every year, accounts for 51% of the annual total dead cause of disease of China.Therefore provide the medicine that more is applicable to the treatment cardiovascular and cerebrovascular disease to become people's problem demanding prompt solution.
The inventor finds that after deliberation HUOXIANG ZHENGQI RUANJIAONANG has the effect of good blood fat reducing, blood glucose or blood pressure.Thereby invented its application in conduct treatment cardiovascular and cerebrovascular diseases medicament preparation.And the application of HUOXIANG ZHENGQI RUANJIAONANG in the pharmaceutical preparation of conduct treatment high fat of blood.The application of HUOXIANG ZHENGQI RUANJIAONANG in the pharmaceutical preparation of conduct treatment hyperglycemia.The application of HUOXIANG ZHENGQI RUANJIAONANG in conduct treatment hypertension disease medicament preparation.Can select for the above-mentioned disease of clinical treatment provides more medication thus.
And the present invention has been done further checking through following experiment.
The specific embodiment
Embodiment 1
The preparation HUOXIANG ZHENGQI RUANJIAONANG can be according to existing drug standard preparation.Also can carry out according to following method.
Take by weighing Rhizoma Atractylodis 195g, Pericarpium Citri Reticulatae 195g, Cortex Magnoliae Officinalis (processed with Rhizoma Zingiberis Recens) 195g, Radix Angelicae Dahuricae 293g, Poria 293g, Pericarpium Arecae 293g, Rhizoma Pinelliae 195g, Radix Glycyrrhizae extractum 24.4g, patchouli oil 1.95ml, Folium perillae acutae oil 0.98ml;
Herba Pogostemonis, Folium Perillae are extracted volatile oil respectively with hydrodistillation; The Radix Angelicae Dahuricae, Pericarpium Citri Reticulatae, Rhizoma Atractylodis, Cortex Magnoliae Officinalis merge with 90-95% alcohol reflux secondary (3 hours for the first time, 2 hours for the second time) secondary filtrating, and concentrating under reduced pressure becomes cream (relative density 1.18-1.20); Rhizoma Pinelliae is used cold water soak, changes water once in per 8 hours, and bubble adds Rhizoma Zingiberis 13.5g decocte with water secondary after extremely passing through the heart again; Poria, Pericarpium Arecae are used the decocting in water secondary, merge with Rhizoma Pinelliae liquid, filter, and are concentrated into 1: 1, and the adjustment of reuse ethanol makes that to contain the alcohol amount be 60%, leaves standstill more than 24 hours, filters, and filtrate decompression is condensed into cream (relative density 112-1.14); Radix Glycyrrhizae extractum is smashed the back and is all dissolved with suitable quantity of water, transfers to that to contain alcohol be 65%, filters, and is condensed into cream (relative density 1.18-1.20).With above each medicament extract mix homogeneously, add phospholipid, Cera Flava, mixing is processed soft capsule, promptly gets.
Embodiment 2
HUOXIANG ZHENGQI RUANJIAONANG is to the influence of rat fat, blood glucose
This experiment proves the beneficial effect that it is used through observing the influence of HUOXIANG ZHENGQI RUANJIAONANG to hyperlipidemia, hyperglycemia model rat blood serum T-CHOL, triglyceride, high density lipoprotein, blood glucose in as treatment hyperlipidemia, hyperglycemia pharmaceutical preparation.
1, materials and methods
HUOXIANG ZHENGQI RUANJIAONANG, Shineway Pharmaceutical Co., Ltd provides, lot number: 09111221
Laboratory animal and grouping: 50 of SD rats, male and female are not limit, average weight 220g, cleaning level Animal House is raised.Be divided into 5 groups at random and be respectively blank group (B), model control group (N), 10 times of groups of HUOXIANG ZHENGQI RUANJIAONANG (L), 20 times of groups of HUOXIANG ZHENGQI RUANJIAONANG (M), 30 times of groups of HUOXIANG ZHENGQI RUANJIAONANG (H), every group each 10.Blank group hormone forage feed, all the other each groups give high glucose and high fat high-energy feed (the about 20KJ/g of total amount of heat), and proportioning normal feedstuff+sucrose+refining Adeps Sus domestica+milk powder=615+0.5+2.5+0.5 is around feeding continuously.
Processing method: after the modeling, each group gives corresponding medicinal liquid, blank control group, model group feedwater, and all the other each groups are respectively by 10,20,30 times of amounts of clinical consumption continuous irrigation stomach.
Observation item: administration rat tail vein at the 0th, 1,3,6,9 weekend is got blood, through centrifuging and taking serum, measures the content of serum total cholesterol (TC), triacylglycerol (TG), HDL-C (HDL-C), blood glucose through automatic biochemistry analyzer.
2, result
Table 1 HUOXIANG ZHENGQI RUANJIAONANG different time to the influence of Serum TC content (
N=10, mmolL
-1)
Compare with blank group (B),
*P＜0.01; Compare with model control group (N),
△P＜0.05,
△ △P＜0.01
Table 2 HUOXIANG ZHENGQI RUANJIAONANG different time to the influence of rat blood serum TG content (
N=10, mmolL
-1)
Compare with blank group (B),
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model control group (N)
Table 3 HUOXIANG ZHENGQI RUANJIAONANG different time to the influence of rat blood serum HDL-C content (
n=10, mmolL-1)
Compare with blank group (B),
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model control group (N)
Table 4 HUOXIANG ZHENGQI RUANJIAONANG different time to the influence of rat blood serum glucose content (
n=10, mmolL-1)
Compare with blank group (B),
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model control group (N)
3, conclusion: above-mentioned experimental result shows, hyperlipidemia, hyperglycemia model rat through 3 weeks above take HUOXIANG ZHENGQI RUANJIAONANG continuously after, blood fat, blood glucose target be improved significantly.
Embodiment 3
HUOXIANG ZHENGQI RUANJIAONANG is to the influence of rat blood pressure
This experiment proves the beneficial effect that it is used through observing the influence of HUOXIANG ZHENGQI RUANJIAONANG to the hypertension model rat in as treatment hypertension drug preparation.
1, materials and methods
HUOXIANG ZHENGQI RUANJIAONANG, Shineway Pharmaceutical Co., Ltd provides, lot number: 09111221
10 of laboratory animal and grouping: normal health WKY (Wistar-Kyoto) male rats, cleaning level, body constitution amount (200 ± 10) g; Original hypertensive rat (spontaneously hypertensive rats, SHR) 40, male, cleaning level, body constitution amount (200 ± 10) g.Adaptability experimentizes after feeding for 1 week.10 of WKY rats are blank group (B), and 40 of SHR rats are divided into 4 groups at random, are respectively model control group (N), 10 times of groups of HUOXIANG ZHENGQI RUANJIAONANG (L), 20 times of groups of HUOXIANG ZHENGQI RUANJIAONANG (M), 30 times of groups of HUOXIANG ZHENGQI RUANJIAONANG (H), every group each 10.
Processing method: each group gives corresponding medicinal liquid, blank control group, model group feedwater, and all the other each groups are respectively by 10,20,30 times of amounts of clinical consumption continuous irrigation stomach.
Observation item: administration detects for the 0th, 1,3,6,9 weekends; After rat being put into (37 ± 1) ℃ electrothermostat preheating 15min before the pressure measurement,, adopt arteria caudalis systolic pressure (SAP), the diastolic pressure (DAP) of rat under the indirect measuring cell mensuration of the non-invasive waking state.
2, result
Table 5 HUOXIANG ZHENGQI RUANJIAONANG different time to the influence of Hypertensive Rats arteria caudalis SAP (
n=10, mmHg)
Compare with blank group (B),
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model control group (N)
Table 6 HUOXIANG ZHENGQI RUANJIAONANG different time to the influence of Hypertensive Rats arteria caudalis DAP (
n=10, mmHg)
Compare with blank group (B),
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model control group (N)
3, conclusion: above-mentioned experimental result shows, the SHR rat through 3 weeks above take HUOXIANG ZHENGQI RUANJIAONANG continuously after, tail vein SAP and DAP all have the therapeutic improvement.But the L group is limited than M, H group action effect on the controlling of blood pressure effect, and the taking dose of prompting HUOXIANG ZHENGQI RUANJIAONANG in the hypertension therapeutic process recommends to use middle and high dosage.
Claims (4)
1. the application of HUOXIANG ZHENGQI RUANJIAONANG in conduct treatment cardiovascular and cerebrovascular diseases medicament preparation.
2. the application of HUOXIANG ZHENGQI RUANJIAONANG in the pharmaceutical preparation of conduct treatment high fat of blood.
3. the application of HUOXIANG ZHENGQI RUANJIAONANG in the pharmaceutical preparation of conduct treatment hyperglycemia.
4. the application of HUOXIANG ZHENGQI RUANJIAONANG in conduct treatment hypertension disease medicament preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104343492A CN102488810B (en) | 2011-12-22 | 2011-12-22 | Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104343492A CN102488810B (en) | 2011-12-22 | 2011-12-22 | Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102488810A true CN102488810A (en) | 2012-06-13 |
| CN102488810B CN102488810B (en) | 2013-11-13 |
Family
ID=46180709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104343492A Active CN102488810B (en) | 2011-12-22 | 2011-12-22 | Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102488810B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103071142A (en) * | 2013-02-26 | 2013-05-01 | 栗明峰 | Quick-acting external patch for tracheitis |
| WO2023109362A1 (en) * | 2021-12-17 | 2023-06-22 | 神威药业集团有限公司 | Method for preparing huoxiangzhengqi soft capsule |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474324A (en) * | 2007-12-31 | 2009-07-08 | 天津中新药业集团股份有限公司达仁堂制药厂 | Ageratum soft capsule and preparation method thereof |
-
2011
- 2011-12-22 CN CN2011104343492A patent/CN102488810B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474324A (en) * | 2007-12-31 | 2009-07-08 | 天津中新药业集团股份有限公司达仁堂制药厂 | Ageratum soft capsule and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 梅全喜，等: "藿香正气丸的临床新用途", 《中药材》 * |
| 陆蔚,等: "藿香正气方药理研究进展", 《中国中医药信息杂志第15卷增刊》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103071142A (en) * | 2013-02-26 | 2013-05-01 | 栗明峰 | Quick-acting external patch for tracheitis |
| WO2023109362A1 (en) * | 2021-12-17 | 2023-06-22 | 神威药业集团有限公司 | Method for preparing huoxiangzhengqi soft capsule |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102488810B (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN102526326A (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
| CN102274252B (en) | Stauntonvine external applied preparation for treating rheumatoid diseases and preparation method thereof | |
| CN102488810B (en) | Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases | |
| CN102139049A (en) | Traditional Chinese medicine for treating diabetic skin pruritus | |
| CN101961386A (en) | Traditional Chinese medicine for treating diabetic skin pruritus | |
| CN104107348A (en) | Chinese herbal medicine for blood sugar reducing, and administration method thereof | |
| CN103550688B (en) | A kind of Chinese medicine composition for the treatment of cardiopalmus | |
| CN103191221A (en) | Antiobesity effect of hedan preparation | |
| CN101152491A (en) | Alopecia treating medicine, preparing method and uses of the same | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN1517115A (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN102028832B (en) | Chinese medical compound emulsion for treating demodicidosis of human bodies and preparation method thereof | |
| CN105012522A (en) | Kidney-nourishing brain-fortifying traditional Chinese medicine, preparation method and purpose | |
| CN106491922B (en) | Traditional Chinese medicine formula medicine suitable for qi stagnation and turbid phlegm type hyperlipemia and capsule thereof | |
| CN104436049A (en) | Traditional Chinese medicine composition for treating heart disease | |
| CN107551054A (en) | Sugared numbness washout side composition, its preparation method and its application | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN102614271A (en) | Chinese medicine for treating diabetic dyslipidemia | |
| CN102715502A (en) | Preparation method of health food with the function of anti-diabetes | |
| CN102614380B (en) | Traditional Chinese medicinal composition pulvis and tablets for treating primary osteoporosis, preparation method thereof and health-care product | |
| CN101698096B (en) | Plaster for treating white vein diseases and preparation method thereof | |
| CN105998629A (en) | Traditional Chinese medicine composition for treating syndrome of qi stagnation and blood stasis | |
| CN1363386A (en) | Composition Chinese-medicinal herb pieces and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: South Luancheng County 051430 Hebei city of Shijiazhuang Province Applicant after: China Shineway Pharmaceutical Group Co., Ltd. Address before: South Luancheng County 051430 Hebei city of Shijiazhuang Province Applicant before: Shineway Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHINEWAY PHARMACEUTICAL CO., LTD. TO: SHINEWAY PHARMACEUTICAL GROUP LIMITED |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |